ImmuCell Reports Q4 2025 Financial Results

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: Mar 04 2026

0mins

ICCC-1.38%

Should l Buy ICCC?

Source: seekingalpha

Financial Overview: ImmuCell reported a GAAP EPS of -$0.31 for Q4 2025, indicating challenges in profitability that reflect ongoing market pressures and cost management issues.
Revenue Decline: The company's revenue for the fourth quarter was $7.62 million, a 1.7% year-over-year decrease, suggesting weak sales growth in a competitive market environment, which may impact future investor confidence.
Market Reaction: Due to the poor financial performance, investors are adopting a cautious outlook on ImmuCell's prospects, potentially leading to stock price volatility that could affect the company's capital-raising capabilities.
Future Outlook: ImmuCell needs to implement effective strategic measures to improve its financial condition in order to address market challenges and restore investor confidence, ensuring sustainable growth.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ICCC?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ICCC

About ICCC

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ImmuCell Corporation Q4 2025 Earnings Call Highlights

Mar 05 2026seekingalpha

Sales Performance: ImmuCell reported product sales of $7.6 million for Q4 2025, a slight decrease of 1.6% compared to Q4 2024, yet domestic sales grew by 8.7% to $7 million, indicating strong performance in the domestic market despite international sales declining to about $600,000 due to order timing issues.
Margin Improvement: The gross margin for Q4 2025 increased to 38%, up from 37% in Q4 2024, while the full-year gross margin rose from 30% to 41%, demonstrating significant progress in cost control and pricing strategies that enhance profitability.
Strategic Shift: Management announced a pivot from Re-Tain manufacturing to focus on the First Defense product line, with plans to increase annual production capacity from 4.6 million units to between 5 million and 6 million units through operational enhancements, reflecting confidence in future growth and market demand.
Financial Health: The company reported a net loss of $1 million for 2025, an improvement from the previous year, with basic net loss per share decreasing from $0.26 to $0.12, while cash on hand stood at $3.8 million and working capital increased to $13 million, indicating robust financial management.